Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(10):1497–1500. doi: 10.1038/bjc.1997.255

Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion.

P J Kuppen 1, L E Jonges 1, C J van de Velde 1, A L Vahrmeijer 1, R A Tollenaar 1, I H Borel Rinkes 1, A M Eggermont 1
PMCID: PMC2223491  PMID: 9166943

Abstract

In this study we determined the level of tumour necrosis factor alpha (TNF-alpha) in liver and tumour tissue samples obtained from patients with colorectal metastases confined to the liver, who were treated with isolated liver perfusion with TNF-alpha and melphalan. We adapted a standard enzyme-linked immunosorbent assay kit for the quantification of TNF-alpha in serum to measure the amount of this cytokine in solid tissue. For this purpose, we developed a buffer that lysed the tissues without affecting the TNF-alpha present. The minimum detection level was about 2 pg of TNF-alpha per mg tissue. Using this technique, we found a significant increase in the TNF-alpha level after perfusion in the liver tissue of all evaluable patients, which may explain the transient liver toxicity we observed in all patients. In tumour tissue, a significant TNF-alpha increase was observed in one out of five patients. The level of TNF-alpha in all liver tissue samples and some of the tumours after treatment by isolated liver perfusion was much higher than the peak serum concentrations obtained after systemic administration of the maximum tolerated dose of TNF-alpha. Furthermore, we demonstrated that the level of TNF-alpha in the liver tissue samples was about seven to eight times higher than in tumour tissue. We concluded that regional liver treatment resulted in a relatively high local level of TNF-alpha, but also that this cytokine did not preferentially accumulate in tumour tissue.

Full text

PDF
1497

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamson G. M., Billings R. E. Tumor necrosis factor induced oxidative stress in isolated mouse hepatocytes. Arch Biochem Biophys. 1992 Apr;294(1):223–229. doi: 10.1016/0003-9861(92)90161-o. [DOI] [PubMed] [Google Scholar]
  2. Blick M., Sherwin S. A., Rosenblum M., Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987 Jun 1;47(11):2986–2989. [PubMed] [Google Scholar]
  3. Cid M. C., Kleinman H. K., Grant D. S., Schnaper H. W., Fauci A. S., Hoffman G. S. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J Clin Invest. 1994 Jan;93(1):17–25. doi: 10.1172/JCI116941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Feinberg B., Kurzrock R., Talpaz M., Blick M., Saks S., Gutterman J. U. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol. 1988 Aug;6(8):1328–1334. doi: 10.1200/JCO.1988.6.8.1328. [DOI] [PubMed] [Google Scholar]
  5. Heller R. A., Krönke M. Tumor necrosis factor receptor-mediated signaling pathways. J Cell Biol. 1994 Jul;126(1):5–9. doi: 10.1083/jcb.126.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hieber U., Heim M. E. Tumor necrosis factor for the treatment of malignancies. Oncology. 1994 Mar-Apr;51(2):142–153. doi: 10.1159/000227329. [DOI] [PubMed] [Google Scholar]
  7. Jättelä M. Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest. 1991 Jun;64(6):724–742. [PubMed] [Google Scholar]
  8. Klaase J. M., Kroon B. B., Eggermont A. M., van Geel A. N., Schraffordt Koops H., Oldhoff J., Liénard D., Lejeune F. J., Berkel R., Franklin H. R. A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer. 1995;31A(1):58–63. doi: 10.1016/0959-8049(94)00372-c. [DOI] [PubMed] [Google Scholar]
  9. Lejeune F., Liénard D., Eggermont A., Schraffordt Koops H., Rosenkaimer F., Gérain J., Klaase J., Kroon B., Vanderveken J., Schmitz P. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma. J Cell Biochem. 1994 Sep;56(1):52–61. doi: 10.1002/jcb.240560110. [DOI] [PubMed] [Google Scholar]
  10. Lienard D., Ewalenko P., Delmotte J. J., Renard N., Lejeune F. J. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992 Jan;10(1):52–60. doi: 10.1200/JCO.1992.10.1.52. [DOI] [PubMed] [Google Scholar]
  11. McIntosh J. K., Mulé J. J., Merino M. J., Rosenberg S. A. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. Cancer Res. 1988 Jul 15;48(14):4011–4017. [PubMed] [Google Scholar]
  12. Prince W. S., Harder K. J., Saks S., Reed B. R., Chen A. B., Jones A. J. ELISA for quantitation of tumor necrosis factor-alpha in serum. J Pharm Biomed Anal. 1987;5(8):793–802. doi: 10.1016/0731-7085(87)80097-3. [DOI] [PubMed] [Google Scholar]
  13. Renard N., Liénard D., Lespagnard L., Eggermont A., Heimann R., Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer. 1994 Jun 1;57(5):656–663. doi: 10.1002/ijc.2910570508. [DOI] [PubMed] [Google Scholar]
  14. Vahrmeijer A. L., van Dierendonck J. H., van de Velde C. J. Treatment of colorectal cancer metastases confined to the liver. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1238–1242. doi: 10.1016/0959-8049(95)00214-4. [DOI] [PubMed] [Google Scholar]
  15. Zimmerman R. J., Chan A., Leadon S. A. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res. 1989 Apr 1;49(7):1644–1648. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES